Seminars in Nuclear Medicine
Volume 35, Issue 2 , Pages 152-158 , April 2005

Teletherapy and radiopharmaceutical therapy of painful bone metastases

  • Edward B. Silberstein, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Edward B. Silberstein, MD, 234 Goodman Street, Nuclear Medicine Division, Department of Radiology, Mont Reid Pavilion, Room G026, Cincinnati, OH 45219.

References 

  1. Foley KM . The treatment of cancer pain . N Engl J Med . 1985;313:84–95
  2. Reddi AH , Roodman D , Freeman C , et al.   Mechanisms of tumor metastasis to bone (Challenges and opportunities) . J Bone Miner Res . 2003;18:190–194
  3. Abrams HL , Spiro R , Goldstein N . Metastases in carcinoma. Analysis of 1000 autopsied cases . Cancer . 1950;23:74–85
  4. World Health Organization . Cancer pain relief and palliative care. Report of a WHO expert committee . In: World Health Organ Tech Rep Ser, 804 . Geneva, Switzerland: World Health Organization; 1990;p. 1–75
  5. Nielsen OS , Munro AJ , Tannock IF . Bone metastases (Pathophysiology and management policy) . J Clin Oncol . 1991;9:509–524
  6. Porter AT , McEwan AJB , Powe JE , et al.   Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer . Int J Rad Oncol Biol Phys . 1993;25:805–813
  7. Tu SM , Millikan RE , Megistu B , et al.   Bone-targeted therapy for androgen-independent carcinoma of the prostate (A randomized Phase II trial) . Lancet . 2001;357:336–341
  8. Sciuto R , Festa A , Rea S , et al.   Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer (A randomized clinical trial) . J Nucl Med . 2002;43:79–86
  9. Greenwald HP , Bonica JJ , Bergner M . The prevalence of pain in four cancers . Cancer . 1987;60:2563–2569
  10. Poulson HS , Neilsen OS , Klee M , et al.   Palliative irradiation of bone metastases . Cancer Treat Rev . 1989;16:41–48
  11. Hoskin PJ . Palliation of bone metastases . Eur J Cancer . 1991;27:950–951
  12. Tong D , Gillick L , Hendrickson FR . The palliation of symptomatic osseous metastases. Final results of the study by the Radiation Therapy Oncology Group . Cancer . 1982;50:893–899
  13. Price P , Hoskin PJ , Easton D , et al.   Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases . Radiother Oncol . 1986;6:247–255
  14. Rose CM , Kagen AR . The final report of the expert panel for the radiation oncology bone metastases working group of the ACR . Int J Radiat Oncol Biol Phys . 1998;40:117–120
  15. Salazar OM , Rubin P , Hendrickson FR , et al.   Single dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group Report . Cancer . 1986;58:29–36
  16. Blake GM , Zivanovic MA , McEwan AJB , et al.   Sr-89 therapy (Strontium kinetics in disseminated carcinoma of the prostate) . Eur J Nuc Med . 1986;12:447–454
  17. Volkert WA , Keutsch EA . Bone-seeking radiopharmaceuticals in cancer therapy . Advances Metals Med . 1991;1:115–153
  18. Samaratunga RC , Thomas SR , Hinnefeld JD , et al.   A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186 (Sn)-HEDP . J Nucl Med . 1995;36:336–350
  19. Urch C . The pathophysiology of cancer-induced bone pain (current understanding) . Palliat Med . 2004;18:267–274
  20. Pandit-Taskar N , Batraki M , Divgi CR . Radiopharmaceutical therapy for palliation of bone pain from osseous metastases . J Nucl Med . 2004;45:1358–1365
  21. Honore P , Rogers SD , Schwei MJ , et al.   Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons . Neuroscience . 2000;98:585–598
  22. Mantyh PW , Clohisy DR , Koltzenburg M , et al.   Molecular mechanisms of cancer pain . Nat Rev Cancer . 2002;2:201–209
  23. Silberstein EB . The treatment of painful osseous metastases with phosphorus-32-labeled phosphates . Semin Oncol . 1993;20(suppl 2):10–21
  24. Nair N . Relative efficacy of 32P and 89Sr in palliation in skeletal metastases . J Nucl Med . 1999;40:256–261
  25. Fettich J , Padhy A , Nair N , et al.   Comparative clinical efficacy and safety of phosphorus-32 and strontium-89 in the palliative treatment of metastatic bone pain (Results of an IAEA coordinated research project) . World J Nucl Med . 2003;2:226–231
  26. Pecher C . Biological investigations with radioactive calcium and strontium (Preliminary report on the use of radioactive strontium in treatment of metastatic bone cancer) . U Cal Public Pharmacol . 1942;11:117–149
  27. Silberstein EB , Williams C . Strontium-89 therapy for the pain of osseous metastases . J Nucl Med . 1985;26:345–348
  28. Robinson RG , Preston DF , Spicer JA , et al.   Radionuclide therapy of intractable bone pain (Emphasis on strontium-89) . Semin Nucl Med . 1992;22:28–32
  29. McEwan AJB , Porter AT , Vennes DM , et al.   An evaluation of the safety and efficacy of treatment with strontium-89 in patients who have previously received wide field radiotherapy . Antibody Immunoconjugates Radiopharm . 1990;3:91–98
  30. Quilty PM , Kirk D , Bolger JJ , et al.   A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer . Radiother Oncol . 1994;31:33–40
  31. Zyskowski A , Lamb D , Morum P , et al.   Strontium-89 treatment for prostate cancer bone metastases (Does a prostate-specific antigen response predict for improved survival?) . Australas Radiol . 2001;45:39–42
  32. Turner SL , Gruenewald S , Spry N , et al.   Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer . Br J Cancer . 2001;84:297–302
  33. Sciuto R , Maini CL , Tofani A , et al.   Radiosensitization with low-dose cisplatin enhances pain palliation in radioisotope therapy with strontium-89 . Nucl Med Commun . 1996;17:799–804
  34. Maxon HR , Thomas SR , Hertzberg VS , et al.   Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases . Semin Nucl Med . 1992;22:33–40
  35. Quirijnen N , Han SH , Zonnenberg BA , et al.   Efficacy of rhenium-186 etidronate in prostate cancer patients with metastatic bone pain . JMSP J Nucl Med . 1996;37:1511–1515
  36. Liepe K , Franke WG , Kropp J , et al.   Comparison of rhenium-188, rhenium-186-HEDP, and strontium-89 in palliation of painful bone metastases . Nuklearmedizin . 2000;39:146–151
  37. Palmedo H , Manka-Waluch A , Albers P , et al.   Repeated bone-targeted therapy for hormone-refractory prostate carcinoma (Randomized phase II trial; with the new, high energy radiopharmaceutical 188Re hydroxyethylidenediphosphonate) . J Clin Oncol . 2003;21:2869–2875
  38. Holmes RA . [153Sm] EDTMP (A potential therapy for bone cancer pain) . Semin Nucl Med . 1992;22:41–45
  39. Dickie GJ , Macfarlane D . Strontium and samarium therapy for bone metastases from prostate carcinoma . Australas Radiol . 1999;43:476–479
  40. Srivastava SC , Atkins HL , Krishnamurthy GT , et al.   Treatment of metastatic bone pain with tin-117m stannic diethyltriaminepentaacetic acid (A phase I/II clinical study) . Clin Cancer Res . 1998;4:61–68
  41. Dafermon A , Colamussi P , Giganti M , et al.   A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer . Eur J Nucl Med . 2001;28:788–798
  42. McEwan AJB , Amyotte GA , McGowan DG , et al.   A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone . Eur Urol . 1994;26(suppl):26–31
  43. Malmberg I , Persson U , Ask A , et al.   Painful bone metastases in hormone-refractory prostate cancer (economic costs of strontium-89 and/or external radiotherapy) . Urol . 1997;50:747–753
  44. Viney RP , Hayne D , Ayra M , et al.   Pharmacological management of metastatic boney pain . Expert Opin Pharmacother . 2004;5:1555–1563
  45. Browne JE , Neville-Webbe H , Coleman RE . The role of bisphosphonates in breast and prostate cancers . Endocr Relat Cancer . 2004;11:207–224
  46. Powles TS , Paterson S , Kanis JA , et al.   Randomized placebo-controlled trial of clodronate in patients with primary operable breast cancer . J Clin Oncol . 2002;20:3219–3224
  47. Roemer-Becuwe C , Krakowski I , Conroy T . Bisphosphonates, pain and quality of life in metastatic breast cancer patients (A literature review) . Bull Cancer . 2003;90:1097–1105

PII: S0001-2998(04)00078-9

doi: 10.1053/j.semnuclmed.2004.11.006

Seminars in Nuclear Medicine
Volume 35, Issue 2 , Pages 152-158 , April 2005

Article Tools